Reid Robison

Reid Robison is CMO at Novamind. Dr Robison is a Physician and Board-Certified Psychiatrist. He is the Co-Founder and Medical Director at Cedar Psychiatry as well as being Medial Director at the Centre for Hope. Additionally, Dr Robison serves as the Coordinating Investigator of the MAPS study investigating MDMA-assisted therapy for eating disorders

Dr Robison has been working with ketamine since 2011 in both research and clinical settings. He was selected as a Principal Investigator by Johnson & Johnson to run a site for their study using IV-ketamine for treatment-resistant depression. Dr Robison has extensively researched the use of ketamine for treating depression as well as for eating disorders.